BRCA2 and breast cancer: While the increased risk of synchronous breast cancer likely results from the increased medical surveillance triggered by the CMM staging protocols, the excess of breast cancer risk (which can be confirmed up until 10 years after the index-CMM) also suggests a potential pathogenetic involvement of BRCA2 and CDKN2A mutations (37–40).